{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:43:59Z","timestamp":1790628239521,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tocilizumab (TCZ), an interleukin-6 receptor antagonist, is recommended as a second-line therapy for thyroid eye disease (TED), yet the clinical determinants of treatment response remain poorly defined. Identifying reliable predictors of response is essential for patient selection and precision use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective cohort study of 234 patients with moderate-to-severe TED treated with intravenous TCZ (8 mg\/kg every 4 weeks) at Beijing Tongren Hospital from January 2023 to December 2025. Treatment response was defined as a reduction in Clinical Activity Score (CAS) of \u22652 points from baseline. Candidate predictors were entered into a multivariate binary logistic regression. ROC analysis identified optimal cut-off values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following TCZ treatment, CAS decreased significantly from 3.42 \u00b1 0.61 to 1.70 \u00b1 0.67 (P &amp;lt; 0.001), and TRAb declined from 10.35 \u00b1 11.99 IU\/L to 4.46 \u00b1 6.73 IU\/L (P &amp;lt; 0.001). Of 234 patients with complete paired data, 155 (66.2%) were Responders. Responders had higher TRAb (12.17 vs. 7.07 IU\/L), fibrinogen (FIB; 2.83 vs. 2.58 g\/L), and HDL-cholesterol (HDL-C; 1.37 vs. 1.24 mmol\/L), and shorter disease duration (7.91 vs. 10.08 months; all P &amp;lt; 0.05). Multivariate analysis identified four independent predictors: shorter disease duration (OR\u00a0=\u00a00.962 per month, 95% CI 0.928\u20130.998, P\u00a0=\u00a00.038), higher TRAb (OR\u00a0=\u00a01.036 per IU\/L, 95% CI 1.004\u20131.068, P\u00a0=\u00a00.025), higher FIB (OR\u00a0=\u00a01.869 per g\/L, 95% CI 1.097\u20133.184, P\u00a0=\u00a00.021), and higher HDL-C (OR\u00a0=\u00a02.665 per mmol\/L, 95% CI 1.175\u20136.041, P\u00a0=\u00a00.019). The composite model achieved AUC\u00a0=\u00a00.695 (95% CI 0.625\u20130.765, P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TCZ produces clinically meaningful and multi-dimensionally validated response with moderate-to-severe TED. Shorter disease duration, higher baseline TRAb, FIB, and HDL-C independently predict response, offering a preliminary framework to inform patient selection. These findings provide the largest real-world evidence to date for guiding precision use of TCZ in TED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1823718","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:21Z","timestamp":1777264101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical predictors of tocilizumab response in moderate-to-severe thyroid eye disease: a large single-center retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ming","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002467","article-title":"Thyroid eye disease: epidemiology, natural history, and risk factors","volume":"39","author":"Bartalena","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000894","article-title":"Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment","volume":"34","author":"Johnson","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1394616","article-title":"Commentary: Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves\u2019 ophthalmopathy: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03845-8","article-title":"Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves\u2019 orbitopathy: a systematic review and meta-analysis","volume":"39","author":"Abumohssin","year":"2025","journal-title":"Eye (Lond)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/ije\/9495296","article-title":"Early low-dose rituximab for mild-to-moderate thyroid eye disease: a preliminary evaluation of efficacy and safety","volume":"2026","author":"Lu","year":"2026","journal-title":"Int J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD012984","DOI":"10.1002\/14651858.CD012984.pub2","article-title":"Tocilizumab for thyroid eye disease","volume":"11","author":"Hamed Azzam","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2528046","article-title":"Cytokines in thyroid-associated ophthalmopathy","volume":"2022","author":"Zhang","year":"2022","journal-title":"J Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2025.2452181","article-title":"Tocilizumab - a disease-modulating treatment for thyroid associated ophthalmopathy","volume":"44","author":"Farde","year":"2025","journal-title":"Orbit"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1470488","article-title":"Update on tocilizumab in rheumatoid arthritis: a narrative review","volume":"16","author":"Parisi","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"Perez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02595-4","article-title":"Efficacy and safety of tocilizumab for thyroid eye disease: a systemic review and meta-analysis","volume":"48","author":"Lin","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf227","article-title":"Long-term tocilizumab therapy in patients with corticosteroid-resistant active moderate-to-severe thyroid eye disease","volume":"193","author":"Dalmas","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/eje-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 receptor tocilizumab in refractory Graves\u2019 orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"Sanchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1614","article-title":"Increased generation of fibrocytes in thyroid-associated ophthalmopathy","volume":"95","author":"Douglas","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.04.004","article-title":"Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis","volume":"126","author":"Sun","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2025.104976","article-title":"Fibrinogen regulates microglial function through the JAK2\/STAT3 signaling pathway","volume":"414","author":"Li","year":"2025","journal-title":"Cell Immunol"},{"key":"B27","article-title":"Involvement of IL-6 and IL-6 receptor in fibrinogen synthesis in the liver of Triton WR-1339-induced hyperlipidemic rats","volume":"18","author":"Ohta","year":"2004","journal-title":"In Vivo"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-06937-0","article-title":"Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia","volume":"43","author":"An","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1781048","article-title":"Incidence and risk factors of tocilizumab-induced hypofibrinogenemia in patients with thyroid eye disease: a single-center retrospective study","volume":"17","author":"Wang","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051061","article-title":"HDL in immune-inflammatory responses: implications beyond cardiovascular diseases","volume":"10","author":"Bonacina","year":"2021","journal-title":"Cells"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13020253","article-title":"High-density lipoprotein alterations in type 2 diabetes and obesity","volume":"13","author":"Denimal","year":"2023","journal-title":"Metabolites"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12967-025-07519-7","article-title":"HDL-C and systemic inflammatory response index mediate the association between visceral adipose tissue and risk of cardiovascular disease among young and middle-aged adults with prediabetes or diabetes: a national cohort study","volume":"24","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvu150","article-title":"HDL in innate and adaptive immunity","volume":"103","author":"Catapano","year":"2014","journal-title":"Cardiovasc Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002573","article-title":"Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review","volume":"40","author":"Duarte","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1038\/s41598-023-36246-6","article-title":"Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis","volume":"13","author":"He","year":"2023","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2023.00142","article-title":"Artificial intelligence and radiomics in magnetic resonance imaging of rectal cancer: a review","volume":"4","author":"Di Costanzo","year":"2023","journal-title":"Explor Target Antitumor Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2017.12.004","article-title":"Texture analysis and machine learning to characterize suspected thyroid nodules and differentiated thyroid cancer: where do we stand","volume":"99","author":"Sollini","year":"2018","journal-title":"Eur J Radiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1823718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:22Z","timestamp":1777264102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1823718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1823718"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1823718","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1823718"}}